期刊文献+

抗骨质疏松治疗的最佳他汀类药物及剂量选择的动物实验研究 被引量:2

Animal experiments of optimal statins drugs and doses of anti-osteoporosis treatment
下载PDF
导出
摘要 目的探索具有最佳抗骨质疏松作用的他汀药物种类和药物剂量,为进一步研究他汀药物同时发挥抗骨质疏松和调脂作用提供基础。方法 40只12月龄新西兰白兔通过双侧卵巢切除和泼尼松龙诱导8周建立骨质疏松症模型,随机分为四组:生理盐水(normal saline,NS)组,瑞舒伐他汀(rosuvastatin,RSV)组,辛伐他汀(simvastatin,Sim)组,阿仑膦酸钠片(Alendronate,ALN)组。RSV组和Sim组按药物浓度梯度分为五个小组。定期测量白兔股骨骨密度(bone mineral desity,BMD)和骨钙素(bone gamma-carboxyglutamic-acid-containing proteins,BGP)、抗酒石酸酸性磷酸酶5b(tartrateresistant acid phosphatase 5b,TRACP-5b)值。结果8周末BMD较0周时明显降低(P<0.05)。12、24和36周末,RSV组、Sim组和ALN组比NS组BMD、BGP水平明显升高,TRACP-5b水平显著降低(P<0.01),并且RSV组与ALN组指标接近(P>0.05)。RSV组内中以60 mg/(kg·d)喂养时,BMD、BGP较其他组明显升高。结论他汀类药物具有抗骨质疏松的作用,效果接近唑来膦酸;亲水性瑞舒伐他汀比疏水性他汀药物作用更佳;并且剂量在60 mg/(kg·d)时效果更好。 Objective To explore the specie and dose of statin who has the best anti-osteoporotic effects,providing the foundation for further study of statins playing the role of anti-osteoporosis and regulating blood lipids.Methods 40 12-month-old New Zealand white rabbits by bilateral ovariectomy and prednisolone-induced for 8 weeks are randomly divided into four groups:normal saline group(NS),rosuvastatin group(RSV),simvastatin group(Sim),Alendronate group(ALN).RSV and Sim are divided into five groups by the dose gradient 20,40,60,80 and 100 mg/(kg·d).White rabbit femur bone mineral density(BMD),bone gamma-carboxyglutamic-acid-containing proteins(BGP)and tartrateresistant acid phosphatase 5b(TRACP-5b)are measured at the 0,8th,12 th,24th,36 th weekends.Results Compared with 0weekend,the rabbits BMD significantly reduced at 8th weekend(P〈0.05).Comparing RSV,Sim and ALN to NS,the BMD and BGP levels are significantly increased,TRACP-5b level are significantly reductive(P〈0.01),and RSV group and ALN datas are close(P〉0.05).In the RSV groups feeded by 60 mg/(kg·d),BMD and BGP are significantly higher than other groups after 12 weeks.Conclusion Statins have anti-osteoporosis effects,closing to zoledronic acid;hydrophilic statin rosuvastatin is more effective than the hydrophobic;and has better results at the dose 60 mg/(kg·d).
出处 《骨科》 CAS 2015年第2期57-61,共5页 ORTHOPAEDICS
基金 广东省中医药局建设中医药强省科研课题资助项目(No.20141257) 深圳市未来产业发展专项资金资助项目(No.CXZZ20140414170821148)
关键词 骨质疏松 他汀类药物 双膦酸盐 骨密度 Osteoporosis Statins Biphosphonates Bone mineral density
  • 相关文献

参考文献22

  • 1Honig S, Rajapakse CS, Chang G. Current treatment approaches to osteoporosis-2013 [J~. Bull Hosp Jt Dis, 2013, 71(3):184 188.
  • 2袁冰,韦卓.骨质疏松症的药物治疗进展[J].骨科,2014,5(2):125-128. 被引量:14
  • 3Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statinsEJ~. Science, 1999, 286(5446) : 1946-1949.
  • 4Thabit A, Alhifany A, Alsheikh R, et al. Effect of simvastatin and atorvastatin on serum vitamin D and bone mineral density in hypercholesterolemic pa- tients: a cross sectional study E Jl. J Osteoporos, 2014:1-9.
  • 5Gotoh M, Mizuno K, Ono Y, et al. Fiuvastatin in creases bone mineral density in postmenopausalwomen[J]. Fukushima J Med Sci, 2011, 57(1) : 19- 27.
  • 6谢莲娜,钟雪焱,王丽君,孙玉兰,王中华,秦颖,刘新荣.阿托伐他汀对老年冠心病患者骨密度的影响[J].临床心血管病杂志,2008,24(2):103-105. 被引量:8
  • 7赵晨,毕擎,胡劲涛,夏冰,应奇峰,朱丹杰,章水均,顾海峰,洪剑飞,邱斌松,陈宇.他汀类药物对高胆固醇绝经后妇女骨密度的影响[J].中华医学杂志,2013,93(29):2309-2311. 被引量:8
  • 8Abel T, Feh4r J. [Role of rosuvastatin in current lipid-lowering therapy~ ]-J~. Orv Hetil, 2010, 151 (35) .- 1424-1428.
  • 9Tsartsalis AN, Dokos C, Kaiafa GD, et al. Statins, bone formation and osteoporosis, hope or hype? ~J~. Hormones (Athens), 2012, 1l(2) ~ 126-139.
  • 10张越,陈思娇,王海平,周敏,胡悦,宋今丹(审校).他汀类药物在骨质疏松症方面的研究新进展[J].中国骨质疏松杂志,2011,17(3):268-271. 被引量:4

二级参考文献127

共引文献112

同被引文献28

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部